VarmX
$67Mtotal raised · 3 rounds on record
$32.4Mlatest round · Series B · May 2023 · 3 yr ago
5backers · BioGeneration Ventures, Inkef
$2.7Mgrants · 1 grant · CORDIS
Overview
About VarmX OUR MISSION To revolutionize the treatment of severe bleeding through a fast, safe, and effective medicine VarmX's VMX-C001 is being developed to facilitate the fast, safe, and effective treatment of severe bleeds in patients that are taking Factor Xa DOACS.
Key facts
These are the key facts about VarmX on Alion as of Nov 13, 2026. It has raised $67M in 2 funding rounds. The latest round is Series B of $32.4M, announced in 2023.
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $67MSum of 2 equity rounds Alion knows
- Latest round
- Series B · $32.4M · May 25, 2023Press report · businesswire.com
Funding and backers
Total raised
$67M
3 rounds on record
Latest round
$32.4M
Series B · May 2023 · 3 yr ago
Team
51-200
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
Backers
5
BioGeneration Ventures, Inkef
The money's age
Long since its last round
41 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 15
Recognition VarmX recognised with two prestigious industry award nominations · varmx.com
Jan 8
Partnership VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization · varmx.com
Sep 16, 2025
Partnership VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment · varmx.com
May 25, 2023
Raised a round Series B $32.4M
Mar 8, 2023
New executive VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer · DutchNews.nl
Sep 1, 2022
Won a grant $2.7M · CORDIS
Jul 8, 2020
Raised a round Series B $34.6M · DutchNews.nl
Jan 2016
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | May 2023 | $32.4M | — | businesswire.com |
| Grant | Sep 2022 | $2.7M | — | CORDIS |
| Series B | Jul 2020 | $34.6M | — | DutchNews.nl |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Discover unparalleled hemorrhage control with iTClamp® – FDA-cleared innovation for swift management of severe bleeding in crucial areas.
Self-Applicable & Life-Saving | Fast, safe, and effective in emergencies | Contact us! | Opportunity Health.
SynaptixBio is a rare disease biotech pioneering ground-breaking development for treatment of severe leukodystrophies which affect the…
Our plant-based technology stops traumatic and surgical bleeds in seconds without the need for manual pressure. Stop bleeding in seconds.
Decoding the microbiome. We design and develop complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and…
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sound BioventuresVia a fund
InnovationQuarterVia a fund
BioGeneration VenturesVia a fund
InkefVia a fund
Ysios CapitalVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
VarmX and CSL Form Strategic Collaboration Effort to Develop VMX-C001 PharmExec
VarmX partners with CSL to advance VMX-C001, a groundbreaking treatment for patients on FXa DOACs, enhancing surgical outcomes and patient care.
Read more
Report
VarmX recognised with two prestigious industry award nominations
Nominated for the 2026 Prix Galien USA "Best Startup" Award, and shortlisted with partner CSL for "Deal of the Year" at the 2026 European Lifestars AwardsLeiden, The Netherlands, 15 September 2026 - VarmX, a biotech company developing innovative approache
Read more
Report
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgeryFirst participant enrolled: EquilibriX-S ...
Read more
Report
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery
VarmX enrols first participant in global Phase 3 EquilibriX-S trial
Read more
Report
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients t
Read more
Report
VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery
First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking FXa inhibitors who require an urgent surgery/procedure, has begun enrolmentGlobal scope: Participant
Read more
Report
VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors
Key HighlightsThe collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for publication in Research and Practice in Thrombosis and Haemostasis and evaluates modified dilute Prothrombi
Read more
Report
New episode of The BioHub Podcast with VarmX's COO Martijn Negen
Episode of The BioHub Podcast featuring our Chief Operating Officer Martijn Negen.In Q4 2025, VarmX signed a strategic collaboration with CSL worth up to $2.1 billion in milestones. This will fully fund a global phase3 trial & pre-launch readiness for the
Read more
Report
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization
Read more
Report
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization
VarmX and Rentschler Biopharma expand collaboration from early development to late-stage and commercial manufacturing of VMX-C001 VMX-C001 builds on strong regulatory momentum, including FDA Fast Track Designation and PMDA Phase 1 waiver, as it progresses
Read more
Report
Show more news
How to cite this page
Alion, "VarmX: key facts", as of Nov 13, 2026. https://alion.io/company/varmx
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0